COSOPT Drug Patent Profile

Which patents cover Cosopt, and what generic alternatives are available?

Cosopt is a drug marketed by Thea Pharma and is included in two NDAs.

The generic ingredient in COSOPT is dorzolamide hydrochloride; timolol maleate. There are fifteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride; timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cosopt

A generic version of COSOPT was approved as dorzolamide hydrochloride; timolol maleate by SANDOZ on November 6^th, 2008.

Summary for COSOPT

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	36
Patent Applications:	494
Drug Prices:	Drug price information for COSOPT
What excipients (inactive ingredients) are in COSOPT?	COSOPT excipients list
DailyMed Link:	COSOPT at DailyMed

See drug prices for COSOPT

See drug sales revenues for COSOPT

Recent Clinical Trials for COSOPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prairie Eye Center	PHASE4
Sengi	PHASE4
Mid Atlantic Retina	Phase 2/Phase 3

See all COSOPT clinical trials

Pharmacology for COSOPT

Drug Class	Carbonic Anhydrase Inhibitor beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists Carbonic Anhydrase Inhibitors

Paragraph IV (Patent) Challenges for COSOPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COSOPT	Ophthalmic Solution	dorzolamide hydrochloride; timolol maleate	2%/0.5%	020869	1	2005-10-11

US Patents and Regulatory Information for COSOPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998	AT1	RX	Yes	Yes
Thea Pharma	COSOPT PF	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	202667-001	Feb 1, 2012	AT2	RX	Yes	Yes

Expired US Patents for COSOPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998
Thea Pharma	COSOPT	dorzolamide hydrochloride; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	020869-001	Apr 7, 1998

International Patents for COSOPT

See the table below for patents covering COSOPT around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	167684
Japan	S57500978
Greece	3007407
Greece	3031467
Germany	10075002
Japan	H05117167	OPHTHALMIC DRUG COMPOSITION CONTAINING COMBINATION OF CARBONATE DEHYDRATASE INHIBITOR WITH BETA-ADRENALIN ANTAGONIST

Supplementary Protection Certificates for COSOPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296879	96C0003	Belgium		PRODUCT NAME: HYDROCHLORIDUM, EQ. DORZOLAMIDUM; NAT. REGISTRATION NO/DATE: 922 IS 168 F13 19951019; FIRST REGISTRATION: SE 12208 19941219
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	CA 2000 00002	Denmark
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306

COSOPT Market Analysis and Financial Projection

Last updated: February 7, 2026

What Is the Market Position of COSOPT?

COSOPT (timolol maleate and dorzolamide hydrochloride) is an ophthalmic solution developed by Merck (also marketed by Novartis in some regions) for glaucoma and ocular hypertension. It competes primarily with fixed-combination therapies containing beta-blockers and carbonic anhydrase inhibitors.

Globally, the glaucoma drug market was valued at approximately USD 5.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030[1]. COSOPT remains a key player with its established efficacy, but faces increasing competition from newer agents like prostaglandin analogs and combination therapies.

How Does COSOPT Fare in the Pharmaceutical Market?

Market Share and Revenue

• COSOPT accounts for an estimated 7-10% of the fixed-combination topical glaucoma therapies in mature markets like North America and Europe[2].

• Its annual sales are estimated at USD 150-200 million, with regional variations influenced by prescribing patterns and patent statuses.

• The product's market share has declined modestly over the past five years due to the introduction of prostaglandin analogs, which command higher patient compliance[3].

Patent and Regulatory Status

• The primary patent for COSOPT expired in 2014 in the US, leading to increased generic competition.

• Generic versions now hold over 80% of the market share in regions where patents have expired, pressure that has driven revenue decline for branded COSOPT products.

• Efforts to extend exclusivity through formulation patents or label extensions have been unsuccessful, limiting revenue prospects.

What Are the Key Drivers of Market Dynamics?

Competitive Landscape

• Prostaglandin analogs like latanoprost, travoprost, and bimatoprost present a more convenient once-daily dosing and have higher patient adherence, eroding COSOPT’s market share.

• Fixed-dose combinations incorporating prostaglandin analogs and beta-blockers offer improved efficacy and convenience.

• Newer pipeline drugs focus on neuroprotection and intraocular pressure (IOP) reduction with fewer side effects.

Regulatory and Reimbursement Factors

• In the US and Europe, formulary decisions increasingly favor newer classes of drugs with better safety profiles, marginalizing older fixed combos like COSOPT.

• Reimbursement policies incentivize the use of drugs with proven safety and convenience, favoring newer agents.

Patent Strategies and Market Entry Barriers

• The original patent expiry prompted generic entry, significantly reducing prices.

• Merck attempted to extend exclusivity via formulation patents, but these measures faced legal challenges.

• Barriers to entry for new formulations are high; however, patent expirations leading to generic proliferation diminish pricing power.

What Is the Financial Trajectory Outlook?

Revenue Forecast

• Projected sales for COSOPT are expected to decline at a CAGR of 5% over the next five years, driven primarily by generic competition and decreasing formulary inclusion.

• In the US, sales could decline by approximately 20-30% over five years due to patent expiry and market share erosion.

Profitability Analysis

• Gross margins for branded COSOPT likely hover at 60-70%, but margins are declining due to price erosion from generics.

• Operating expenses associated with marketing and legal defense of patents have decreased, but R&D reinvestment in glaucoma pipeline drugs remains a priority for manufacturers.

Strategic Opportunities

• Lifecycle expansion through reformulation (e.g., preservative-free formulations) may stabilize revenues slightly.

• Licensing or partnering opportunities for combination therapies that include COSOPT's components could sustain some revenue streams.

Risks to Financial Trajectory

• Accelerated market shift toward new therapies.

• Regulatory setbacks for reformulation efforts.

• Pricing pressures from increased generic competition.

Summary of Key Market Drivers and Financial Outlook

Parameter	Current Status	Future Trend
Market Share (branded COSOPT)	7-10% of fixed-combo glaucoma therapies	Declining as generics gain prominence
Sales (global)	USD 150-200 million annually	Decline at ~5% CAGR over 5 years
Patent expiry	US patent expired 2014; other regions vary	Increased generic penetration
Entry of generics	Over 80% market share in regions with patent expiration	Continues to press down prices
Market growth rate	~4.8% CAGR (overall glaucoma market)	Overall growth but branded drug share declines

Key Takeaways

• COSOPT remains a significant glaucoma therapy but faces diminishing market share due to patent expiration and competition from prostaglandin analogs.

• Revenues are expected to decline steadily; strategic reformulations or new indications could slow this trend.

• The market is highly competitive with increasing reliance on generics, affecting margins and pricing power.

---

FAQs

1. What factors led to the decline in COSOPT’s market share?
Patent expiration, the rise of prostaglandin analogs with better adherence profiles, and pricing pressure from generics contributed to the decline.

2. Are there ongoing efforts to extend COSOPT’s patent protection?
Merck pursued formulation patents, but legal challenges and patent expirations have limited success in extending exclusivity.

3. How does the competition from generics impact the profitability of COSOPT?
Generic competition drives prices lower, reducing profit margins and overall revenue for branded formulations.

4. What are the prospects for reformulating COSOPT to regain market share?
Reformulations like preservative-free versions could appeal to certain patient segments but face regulatory approval and patent challenges.

5. What opportunities exist for pipeline drugs targeting glaucoma?
Innovations focused on neuroprotection, sustained release formulations, and combination therapies are expected to influence the future market landscape.

---

References

[1] Grand View Research, "Glaucoma Drugs Market Size & Trends," 2022.
[2] IQVIA, "Global Ophthalmic Market Share Analysis," 2023.
[3] EvaluatePharma, "Pharmaceutical Market Trends," 2022.